Antitumor effect of recombinant mouse interleukin-33 in mice

JIANG Liya; LUO Ping; DENG Shaorong; YE Hao; YU Yan; HAN Wei

doi:10.11665/j.issn.1000-5048.20200510

Journal of China Pharmaceutical University > 2020 > 51(5): 584-590. > DOI: 10.11665/j.issn.1000-5048.20200510

JIANG Liya, LUO Ping, DENG Shaorong, YE Hao, YU Yan, HAN Wei. Antitumor effect of recombinant mouse interleukin-33 in mice[J]. Journal of China Pharmaceutical University, 2020, 51(5): 584-590. DOI: 10.11665/j.issn.1000-5048.20200510

Citation:

PDF (635 KB)

Antitumor effect of recombinant mouse interleukin-33 in mice

Funds: This study was supported by the National Natural Science Foundation of China (No.81673446/H3105)

More Information

Received Date: November 17, 2019
Revised Date: September 21, 2020

Graphical Abstract

Abstract

Abstract

To explore the effect of IL-33 on various tumor types,exogenous injection of recombinant mouse IL-33 protein (mIL-33) was used to study the efficacy of different subcutaneous tumor-bearing mouse models. In this study,mIL-33 has been found to significantly inhibit the growth of liver,lung,gastric,prostate,and colon cancers. However,the inhibition of tumor growth by mIL-33 was not completely consistent in different types of tumor. A lower dose of mIL-33 (10 μg/kg) significantly inhibited tumor growth in subcutaneous tumor-bearing mice of liver,lung,and gastric cancers,while a higher dose of mIL-33 (90 μg/kg) was required to exert the corresponding antitumor effect in subcutaneous tumor-bearing mouse models with prostate and colon cancers. In addition,the growth inhibitory effect of mIL-33 on subcutaneous tumors of colon cancer was also correlated with the duration of administration and the stage of tumor progression. The results of this study indicate that mIL-33 significantly inhibits the growth of a variety of tumors,suggesting that IL-33 might be an effective target for tumor treatment.
- mIL-33,
- antitumor,
- liver cancer,
- lung cancer,
- prostate cancer,
- colon cancer

FullText(HTML)

References (23)

References

[1]	. Immunol Rev，2018，281（1）：154?168.
[2]	de la Fuente M，MacDonald TT，Hermoso MA. The IL-33/ST2 axis：role in health and disease［J］. Cytokine Growth Factor Rev，2015，26（6）：615?623.
[3]	Yang Y，Wang JB，Li YM，et al. Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma［J］. Oncol Lett，2016，12（1）：429?436.
[4]	Zhang P，Liu XK，Chu Z，et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications［J］. J Int Med Res，2012，40（5）：1654?1661.
[5]	Jin ZQ，Lei L，Lin DD，et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4⁺ and CD8⁺ T cell responses in hepatocellular carcinoma［J］. J Immunol，2018，201（12）：3770?3779.
[6]	Deng X，Xiong YQ，Ma B，et al. Expression of interleukin-33 in non-small cell lung cancer patients and its clinical significance［J］. Chin J Exp Surg（中华实验外科杂志），2016，33（4）：1122?1125.
[7]	Gao K，Li XY，Zhang L，et al. Transgenic expression of IL-33 activates CD8⁺ T cells and NK cells and inhibits tumor growth and metastasis in mice［J］. Cancer Lett，2013，335（2）：463?471.
[8]	Deng KY，Wang H，Shan T，et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33［J］. Sci Rep，2016，6：24505.
[9]	Eissmann MF，Dijkstra C，Jarnicki A，et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization［J］. Nat Commun，2019，10（1）：2735.
[10]	Saranchova I，Han J，Huang H，et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33［J］. Sci Rep，2016，6：30555.
[11]	Zhou YX，Ji Y，Wang HG，et al. IL-33 promotes the development of colorectal cancer through inducing tumor-infiltrating ST2L⁺ regulatory T cells in mice［J］. Technol Cancer Res Treat，2018，17：1533033818780091.
[12]	Zhang Y，Davis C，Shah S，et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis［J］. Mol Carcinog，2017，56（1）：272?287.
[13]	Xia YL，Ohno T，Nishii N，et al. Endogenous IL-33 exerts CD8⁺ T cell antitumor responses overcoming pro-tumor effects by regulatory T cells in a colon carcinoma model［J］. Biochem Biophys Res Commun，2019，518（2）：331?336.
[14]	O''''Donnell C，Mahmoud A，Keane J，et al. An antitumorigenic role for the IL-33 receptor，ST2L，in colon cancer［J］. Br J Cancer，2016，114（1）：37?43.
[15]	Eissmann MF，Dijkstra C，Wouters MA，et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-γ-dependent manner［J］. Cancer Immunol Res，2018，6（4）：409?421.
[16]	Luo P，Deng SR，Ye H，et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling［J］. Biomed Pharmacother，2020，127：110232.
[17]	Gao Q，Han Y，Xu W，et al. Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models［J］. J China Pharm Univ（中国药科大学学报），2020，51（2）：206?212.
[18]	Deng SR，Deng Q，Zhang YJ，et al. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer［J］. Cancer Lett，2019，443：1?12.
[19]	Wang KL，Shan S，Yang ZJ，et al. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model［J］. Oncotarget，2017，8（40）：68571?68582.
[20]	Wang CH，Chen ZS，Bu XM，et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer［J］. Biochem Biophys Res Commun，2016，479（3）：461?468.
[21]	He ZX，Chen LL，Souto FO，et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc ^Min/+ mice［J］. Sci Rep，2017，7（1）：5520.
[22]	Lu BF，Yang M，Wang QQ. Interleukin-33 in tumorigenesis，tumor immune evasion，and cancer immunotherapy［J］. J Mol Med，2016，94（5）：535?543.
[23]	Fournié JJ，Poupot M. The pro-tumorigenic IL-33 involved in antitumor immunity：a Yin and Yang cytokine［J］. Front Immunol，2018，9：2506.

[1]	YU Juping, LIU Wei, YE Meng, TANG Dongyang, GAO Xiangdong. Effect of homologous overexpression of nucleoside diphosphate kinase on the yield and molecular weight of hyaluronic acid[J]. Journal of China Pharmaceutical University, 2022, 53(2): 232-238. DOI: 10.11665/j.issn.1000-5048.20220214
[2]	JIANG Liya, LUO Ping, DENG Shaorong, YE Hao, YU Yan, HAN Wei. Antitumor effect of recombinant mouse interleukin-33 in mice[J]. Journal of China Pharmaceutical University, 2020, 51(5): 584-590. DOI: 10.11665/j.issn.1000-5048.20200510
[3]	LI Chengfei, CHEN Ling, WU Xuri. Regio-selective glycosylation of mogroside IIIE by glycosyltransferase[J]. Journal of China Pharmaceutical University, 2019, 50(2): 222-229. DOI: 10.11665/j.issn.1000-5048.20190214
[4]	JIN Yue, WU Xuri, CHEN Yijun. Applications of glycosyltransferases in the improvement of druggability of natural products[J]. Journal of China Pharmaceutical University, 2017, 48(5): 529-535. DOI: 10.11665/j.issn.1000-5048.20170504
[5]	XIA Yang, HU Lingling, CHEN Jiao, LU Wuguang, YAN Huaijiang, HUO Jiege, CAO Peng. Cloning and expression of recombinant BmkNaTx12, a new voltage-gated sodium channel from scorpion Buthus martensii Karsch[J]. Journal of China Pharmaceutical University, 2017, 48(2): 220-226. DOI: 10.11665/j.issn.1000-5048.20170214
[6]	WANG Yuanxi, CHEN Junsheng, SHAO Lei, LI Ji′an, LIN Huimin, CHEN Daijie. Heterologous expression and in vitro activity of vancomycin glycosyltransferase GtfE[J]. Journal of China Pharmaceutical University, 2013, 44(3): 272-276. DOI: 10.11665/j.issn.1000-5048.20130317
[7]	ZHAO Na, SUN Hong-bin. Poly(ADP-ribose) polymerase inhibitors and synthetic lethality[J]. Journal of China Pharmaceutical University, 2012, 43(2): 107-112.
[8]	LIN Yu-shuang, HONG Wen-rong. Construction of Streptomyces tenebrarius mutant with knockout of tobS1-C genes[J]. Journal of China Pharmaceutical University, 2012, 43(1): 92-96.
[9]	Construction of a high epidaunorubicin-producing strain by gene recombination[J]. Journal of China Pharmaceutical University, 2010, 41(3): 283-288.
[10]	PENG Chen, GE Hao, HE Shu-ying, GAO Xiang-dong. Molecular cloning，expression and identification of recombinant hyaluronan synthase from Pasteurella multocida[J]. Journal of China Pharmaceutical University, 2009, 40(6): 549-552.

Cited By

Cited by

Periodical cited type(1)

马小翔，马泽源，刘亚月，周龙建，和羿帆，张翼. 仿突变生物合成调控对土曲霉C23-3次生代谢产物的影响. 生物技术通报. 2024(08): 275-287 .

Other cited types(0)

Get Citation

PDF

XML

Article views (155) PDF downloads (529) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Antitumor effect of recombinant mouse interleukin-33 in mice

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Antitumor effect of recombinant mouse interleukin-33 in mice

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content